Kairos Pharma, Ltd. (KAPA)

Kairos Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	4.49	1.27	0.09	0.44	0.07
Cash & Short-Term Investments	4.49	1.27	0.09	0.44	0.07
Cash Growth	253.07%	1267.74%	-78.72%	498.63%	410.20%
Other Current Assets	0.9	2.9	0.01	-	-
Total Current Assets	5.39	4.17	0.1	0.44	0.07
Other Intangible Assets	0.06	0.22	0.38	0.54	0.7
Other Long-Term Assets	1.09	1.38	0.48	0.06	-
Total Assets	6.54	5.77	0.97	1.04	0.78
Accounts Payable	0.2	0.99	2.41	1.63	1.56
Short-Term Debt	-	-	-	-	0.38
Total Current Liabilities	0.2	0.99	2.41	1.63	1.94
Long-Term Debt	-	-	0.64	0.58	-
Total Long-Term Liabilities	-	-	0.64	0.58	-
Total Liabilities	0.2	0.99	3.04	2.22	1.94
Common Stock	0.02	0.01	0.01	0.01	0.01
Additional Paid-in Capital	20.58	13.58	4.12	3.21	2.17
Retained Earnings	-	-	-6.21	-4.4	-3.35
Shareholders' Equity	6.34	4.78	-2.08	-1.18	-1.17
Total Liabilities & Equity	6.54	5.77	0.97	1.04	0.78
Total Debt	0	0	0.64	0.58	0.38
Net Cash (Debt)	4.49	1.27	-0.55	-0.15	-0.31
Net Cash Growth	253.07%	-	-	-	-
Net Cash Per Share	0.24	0.11	-0.05	-0.01	-0.03
Book Value	6.34	4.78	-2.08	-1.18	-1.17
Book Value Per Share	0.34	0.42	-0.20	-0.12	-0.13
Tangible Book Value	6.28	4.55	-2.46	-1.72	-1.87
Tangible Book Value Per Share	0.34	0.40	-0.24	-0.17	-0.20

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q